MarketPeel
Pricing
…
WN

Weston Nichols

TCRX
10% OWNER · TSCAN THERAPEUTICS, INC. · CIK 0001746376
FILING MIX · LIFETIME94%/6%
BUYS
44
SELLS
3
TOTAL VALUE
$87.73M
COMPANIES
6
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
20,098,940
AVG SELL PX
$2.52
TRADE KIND
SHOWING 47 / 47
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
33 backtested trades · 8 horizons · 46 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Weston Nichols, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d33+66.67%+12.66%+0.48%+12.17%+10.80%4.50
14d33+69.70%+9.95%+1.26%+8.69%+9.56%3.90
30d33+60.61%+10.21%+1.50%+8.72%+5.37%2.95
60d33+69.70%+13.87%+3.20%+10.53%+9.57%1.86
90d33+63.64%+14.47%+2.79%+11.68%+19.73%2.06
180d33(1 pending)+53.13%+33.10%+4.85%+28.24%+12.48%2.35
1y33(16 pending)+0.00%+13.71%+18.08%-4.37%-42.57%—
2y33(29 pending)+75.00%-48.13%+44.92%-93.05%-82.74%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TCRX · 8,019,148 shares · as of Dec 23, 2025
02,004,7874,009,5746,014,3618,019,14820242025SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 44 buys / 3 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KRRO
KORRO BIO, INC.
PURCHASE
1,462$13.19$19.3K1,544,980Aug 10, 2026Aug 13, 2026 ↗View →
KRRO
KORRO BIO, INC.
PURCHASE
5,222$11.40$59.5K1,543,518Aug 6, 2026Aug 13, 2026 ↗View →
PASG
PASSAGE BIO, INC.
PURCHASE
50,055$4.12$206.1K673,759Jun 25, 2026Jun 29, 2026 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
9,730——9,730Jun 18, 2026Jun 22, 2026 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
5,925——22,225Jun 18, 2026Jun 22, 2026 ↗View →
KRRO
KORRO BIO, INC.
PURCHASE
520$10.60$5.5K1,538,296Mar 31, 2026Apr 2, 2026 ↗View →
TCRX
TSCAN THERAPEUTICS, INC.
PURCHASE
6,232$0.90$5.6K8,019,148Dec 23, 2025Dec 23, 2025 ↗View →
TCRX
TSCAN THERAPEUTICS, INC.
PURCHASE
75,500$0.90$68.0K8,012,916Dec 22, 2025Dec 23, 2025 ↗View →
TCRX
TSCAN THERAPEUTICS, INC.
PURCHASE
80,069$0.90$72.0K7,937,416Dec 19, 2025Dec 23, 2025 ↗View →
CGEM
CULLINAN THERAPEUTICS, INC.
PURCHASE
165,667$8.40$1.39M8,963,500Oct 28, 2025Oct 30, 2025 ↗View →
NEUP
NEUPHORIA THERAPEUTICS INC.
PURCHASE
639,110$5.14$3.28M875,328Oct 21, 2025Oct 23, 2025 ↗View →
CGEM
CULLINAN THERAPEUTICS, INC.
PURCHASE
32,217$7.84$252.6K8,797,833Oct 17, 2025Oct 21, 2025 ↗View →
CGEM
CULLINAN THERAPEUTICS, INC.
PURCHASE
150,000$8.86$1.33M8,765,616Oct 16, 2025Oct 21, 2025 ↗View →
CGEM
CULLINAN THERAPEUTICS, INC.
PURCHASE
51,500$7.94$409.0K8,615,616Oct 15, 2025Oct 21, 2025 ↗View →
CGEM
CULLINAN THERAPEUTICS, INC.
PURCHASE
15,032$7.59$114.0K8,564,116Oct 14, 2025Oct 21, 2025 ↗View →
CGEM
CULLINAN THERAPEUTICS, INC.
PURCHASE
277,298$7.36$2.04M8,549,084Oct 10, 2025Oct 10, 2025 ↗View →
CGEM
CULLINAN THERAPEUTICS, INC.
PURCHASE
626,043$6.70$4.19M8,271,786Oct 9, 2025Oct 10, 2025 ↗View →
CGEM
CULLINAN THERAPEUTICS, INC.
PURCHASE
556,300$6.46$3.59M7,645,743Oct 8, 2025Oct 10, 2025 ↗View →
PASG
PASSAGE BIO, INC.
PURCHASE
11,900$6.99$83.2K623,704Sep 15, 2025Sep 15, 2025 ↗View →
PASG
PASSAGE BIO, INC.
PURCHASE
19,783$6.99$138.3K611,804Sep 12, 2025Sep 15, 2025 ↗View →
PASG
PASSAGE BIO, INC.
PURCHASE
325$6.96$2.3K592,021Sep 11, 2025Sep 15, 2025 ↗View →
PASG
PASSAGE BIO, INC.
PURCHASE
66,423$5.71$379.5K591,696Jul 24, 2025Jul 24, 2025 ↗View →
PASG
PASSAGE BIO, INC.
PURCHASE
49,302$5.74$283.0K525,273Jul 23, 2025Jul 24, 2025 ↗View →
PASG
PASSAGE BIO, INC.
PURCHASE
13,123$5.44$71.3K475,971Jul 22, 2025Jul 24, 2025 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
10,350——10,350Jun 11, 2025Jun 13, 2025 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
6,900——16,300Jun 11, 2025Jun 13, 2025 ↗View →
TCRX
TSCAN THERAPEUTICS, INC.
PURCHASE
1,200,000$1.20$1.44M7,946,141May 20, 2025May 21, 2025 ↗View →
TCRX
TSCAN THERAPEUTICS, INC.
PURCHASE
1,388,794$1.20$1.67M6,746,141May 19, 2025May 21, 2025 ↗View →
PASG
PASSAGE BIO, INC.
PURCHASE
373,645$0.65$241.0K9,256,953Dec 27, 2024Dec 31, 2024 ↗View →
TCRX
TSCAN THERAPEUTICS, INC.
PURCHASE
7,500,000$4.00$30.00M7,500,000Dec 26, 2024Dec 30, 2024 ↗View →
TCRX
TSCAN THERAPEUTICS, INC.
PURCHASE
100,000$2.90$290.1K5,357,347Dec 13, 2024Dec 16, 2024 ↗View →
TCRX
TSCAN THERAPEUTICS, INC.
PURCHASE
31,800$3.01$95.6K5,257,347Dec 12, 2024Dec 16, 2024 ↗View →
PASG
PASSAGE BIO, INC.
PURCHASE
29,300$0.67$19.7K8,883,308Nov 27, 2024Nov 27, 2024 ↗View →
PASG
PASSAGE BIO, INC.
PURCHASE
167,055$0.71$118.2K8,854,008Nov 26, 2024Nov 27, 2024 ↗View →
PASG
PASSAGE BIO, INC.
PURCHASE
259,998$0.56$146.7K8,686,953Nov 25, 2024Nov 27, 2024 ↗View →
TCRX
TSCAN THERAPEUTICS, INC.
PURCHASE
947$4.34$4.1K5,225,547Nov 15, 2024Nov 19, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
3,400——9,400Jun 7, 2024Jun 11, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
12,500——12,500Jun 7, 2024Jun 11, 2024 ↗View →
TCRX
TSCAN THERAPEUTICS, INC.
PURCHASE
5,000,000$7.13$35.65M5,000,000Apr 19, 2024Apr 23, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
6,000——6,000Jun 16, 2023Jun 21, 2023 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
17,500——17,500Jun 16, 2023Jun 21, 2023 ↗View →
TCRX
TSCAN THERAPEUTICS, INC.
SALE
10,000$2.51$25.1K5,240,000May 31, 2023Jun 2, 2023 ↗View →
TCRX
TSCAN THERAPEUTICS, INC.
SALE
400$2.51$1.0K5,224,600May 31, 2023Jun 2, 2023 ↗View →
TCRX
TSCAN THERAPEUTICS, INC.
SALE
15,000$2.52$37.8K5,225,000May 31, 2023Jun 2, 2023 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
17,500——17,500Jun 17, 2022Jun 21, 2022 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
17,500——17,500Jun 22, 2021Jun 23, 2021 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
12,500——12,500Jun 19, 2020Jun 22, 2020 ↗View →
Other insiders · TCRX
Loading peer insiders…
About this filer
CIK 0001746376
ROLE
10% Owner
PRIMARY
TCRX
COMPANIES
6
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001746376DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback